Marcus W. Bosenberg

Dermatology
15 York St
New Haven, CT 6510.

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 202 publications

Targeting DNMT1 augments anti-tumor CD8⁺ T cell function.

Targeting DNMT1 augments anti-tumor CD8⁺ T cell function.

Journal: bioRxiv : the preprint server for biology
Published: July 17, 2026

CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells.

CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells.

Journal: iScience
Published: November 20, 2025

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Journal: Nature
Published: October 30, 2025

Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.

Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.

Journal: Cancer immunology research
Published: July 21, 2025

Clonal determinants of organotropism and survival in metastatic uveal melanoma.

Clonal determinants of organotropism and survival in metastatic uveal melanoma.

Journal: NPJ precision oncology
Published: July 15, 2025

Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade.

Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade.

Journal: Molecular cancer therapeutics
Published: June 16, 2025

PIP4K2A/2B inhibitor suppresses tumor growth in a xenograft model of NSCLC.

PIP4K2A/2B inhibitor suppresses tumor growth in a xenograft model of NSCLC.

Journal: iScience
Published: June 03, 2025

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responses.

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responses.

Journal: Research square
Published: May 05, 2025

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses.

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses.

Journal: Cancer immunology, immunotherapy : CII
Published: February 13, 2025

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 29, 2024

Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance.

Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance.

Journal: bioRxiv : the preprint server for biology
Published: November 18, 2024

Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma.

Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma.

Journal: Cell reports
Published: November 16, 2024
Showing 1-12 of 202

Last Updated: 09/26/2026